All Posts

How medtech survives the SaaSpocolypes

Feb 5, 2026

•

9 min read

How the analysts separate signal from noise

Feb 4, 2026

•

13 min read

The Platform Was the Prize: The Starpharma (ASX: SPL) Story

Feb 3, 2026

•

12 min read

What Happens After the Gold Rush? From Miners to Molecules

Feb 2, 2026

•

10 min read

Is the RAT Back? The Return of Rapid Point-of-Care Diagnostics

Jan 30, 2026

•

12 min read

My playbook for "confession season", also known as quarterly season

Jan 29, 2026

•

9 min read

Hunting for the Next 4DX: The EchoIQ (ASX: EIQ) story

Jan 28, 2026

•

12 min read

The Hard Pivot: What happens after a biotech reboots?

Jan 27, 2026

•

11 min read

The $2m Oversight: Don't forget to Exercise

Jan 23, 2026

•

5 min read

Big Volume, Boring News: Why Stocks Move on “Nothing”

Jan 22, 2026

•

9 min read

Explained: Why Options Magnify Risk and Reward

Jan 21, 2026

•

12 min read

Whale Watching: What is driving the share price?

Jan 20, 2026

•

10 min read

1...8 9 10 11 12 13

All Posts

How medtech survives the SaaSpocolypes

How the analysts separate signal from noise

The Platform Was the Prize: The Starpharma (ASX: SPL) Story

What Happens After the Gold Rush? From Miners to Molecules

Is the RAT Back? The Return of Rapid Point-of-Care Diagnostics

My playbook for "confession season", also known as quarterly season

Hunting for the Next 4DX: The EchoIQ (ASX: EIQ) story

The Hard Pivot: What happens after a biotech reboots?

The $2m Oversight: Don't forget to Exercise

Big Volume, Boring News: Why Stocks Move on “Nothing”

Explained: Why Options Magnify Risk and Reward

Whale Watching: What is driving the share price?

The Armchair Analyst